The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program Home
Abstract Details
|
Activity Number:
|
616
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Thursday, August 2, 2012 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #306124 |
|
Title:
|
Determinations of Dilution Series and Sample Sizes in Quantal Bioassays
|
|
Author(s):
|
Qianqiu Li*+ and Bill Pikounis and Justin Smith
|
|
Companies:
|
Janssen Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc. and Mentor Corporation
|
|
Address:
|
1400 McKean Road, Spring House, PA, 19477, United States
|
|
Keywords:
|
Optimal designs ;
Quantal bioassay ;
LD50 ;
Potency ;
Sample size calculation ;
Logit and probit models
|
|
Abstract:
|
In quantal bioassays, a binary response can be related to different levels of a stimulus or dilution series via logit and probit models. Two common and important design issues are to determine optimal arrangement of the dilution series and the appropriate sample sizes given target design criteria and objectives. Based on both logit and probit models at six dilution levels, we employ locally D-optimal and A-optimal criteria along with desirable constraints (symmetry at zero for log10 scaled dilution levels or thresholds for the lowest and highest dilution levels). The design optimality and its association with constrained design space are demonstrated via efficiency measures. In addition, we present sample size calculation in terms of LD50 and potency.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2012 program
|
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.